<p><i><strong>Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market ...

<p><i><strong>Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy</strong></i></p> <p><strong id="dateline">KELOWNA, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 1, 2026 / </strong>Lexaria Bioscience Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/LEXX">LEXX</a>) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today announced the launch of <i>Reformulated: Into the Mainstream</i>, an ongoing investor communications series designed to support transparency, consistent engagement, and alignment with shareholders and the broader investment community.</p><p>As Lexaria continues executing its strategy within the rapidly evolving GLP-1 and oral drug delivery landscape, the video series will feature regular interviews and management discussions with Lexaria leadership. Episodes will cover company updates alongside broader market and sector trends, providing investors with consistent context around Lexaria's business and the environment in which it operates.</p><p>The inaugural episode features an in-depth conversation with Lexaria CEO Rich Christopher and host Ana Berry. The discussion covers the DehydraTECH platform and its applicability across GLP-1 therapies, CBD, antivirals, and other compounds; the Company's focus on the GLP-1 market, which generated approximately $75 billion in worldwide revenue in 2025; the completion of five human GLP-1 studies across semaglutide, tirzepatide, and liraglutide; and Lexaria's multi-pronged commercial strategy, including outlicensing activity under an active Material Transfer Agreement with a global pharmaceutical company.</p><p>The first installment of <i>Reformulated: Into the Mainstream</i> is now available here: <a rel="nofollow" href="https://pr.report/l7bp">https://www.youtube.com/watch?v=KG9dCWS6x6I</a></p><p>"Transparency and consistent communication are foundational to building long-term trust with shareholders," said Rich Christopher, CEO of Lexaria. "The series reflects our commitment to providing ongoing insight into how we think about oral drug delivery, the GLP-1 opportunity, and the disciplined execution required to advance DehydraTECH toward commercial partnerships."</p><p>New episodes will be released periodically, expanding into additional areas of Lexaria's clinical pipeline, intellectual property portfolio, and industry developments.</p><p><strong>About Lexaria Bioscience Corp. & DehydraTECH</strong></p><p>DehydraTECH<sup>&#8482;</sup> is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery. DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 65 patents granted and additional patents pending worldwide. For more information, please visit <a rel="nofollow" href="https://pr.report/l7bq">www.lexariabioscience.com</a>.</p><p><i><strong>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</strong></i></p><p><i>This press release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, statements by the Company relating to the intended use of proceeds from the offering and relating to the Company's ability to carry out research initiatives, receive regulatory approvals or grants or experience positive effects or results from any research or study. Such forward-looking statements are estimates reflecting the Company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, market and other conditions, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company's ability to maintain existing collaborations and realize the benefits thereof, delays or cancellations of planned R&D that could occur related to pandemics or for other reasons, and other factors which may be identified from time to time in the Company's public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. The Company provides links to third-party websites only as a courtesy to readers and disclaims any responsibility for the thoroughness, accuracy or timeliness of information at third-party websites. There is no assurance that any of Lexaria's postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease. Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements or links to third-party websites contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</i></p><p><strong>INVESTOR CONTACT:</strong><br/>George Jurcic - Head of Investor Relations<br/><a rel="nofollow" href="mailto:ir@lexariabioscience.com">ir@lexariabioscience.com</a><br/>Phone: 250-765-6424, ext. 202</p><p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p><br/><br/>View the original <a href='https://www.accessnewswire.com/newsroom/en/consumer-and-retail-products/lexaria-bioscience-launches-ongoing-investor-video-series-to-expand-sh-1163045'>press release</a> on ACCESS Newswire<br/><br/>
      <img src="https://app.accessnewswire.com/img.ashx?id=1163045" width="0" height="0"/>

LEXX

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Lexaria Bioscience Introduces Investor Series on GLP-1 Market Strategy

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;p&gt;&lt;i&gt;&lt;strong&gt;Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market ...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Lexaria Bioscience has launched an investor communication series focusing on its DehydraTECH platform and the lucrative GLP-1 market. The ongoing series aims to enhance transparency with shareholders and highlights the company&#039;s strategic advancements in oral drug delivery, suggesting a potential boost in investor confidence and stock performance.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Lexaria launches &#039;Reformulated: Into the Mainstream&#039; investor series for transparency.</li><li>CEO discusses DehydraTECH application in the $75 billion GLP-1 market.</li><li>Five human GLP-1 studies completed with major pharmaceutical partnership underway.</li><li>Series aims to provide context on market trends and Lexaria&#039;s strategy.</li><li>Investor outreach to enhance shareholder engagement and trust.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Lexaria Bioscience Corp. (LEXX)</strong>: Focuses on GLP-1 therapies and oral drug delivery innovations.</li><li><strong>Major Pharmaceutical Company (N/A)</strong>: Partnering with Lexaria through Material Transfer Agreement on GLP-1 studies.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This fits under &#039;Corporate Developments&#039; as Lexaria is strengthening its investor relations through an ongoing communications series, which may enhance shareholder confidence and support price stability.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Completion of human GLP-1 studies may attract further partnerships.</li><li>GLP-1 market&#039;s $75 billion revenue potential can enhance LEXX&#039;s valuation.</li><li>Increased investor transparency could positively influence stock price.</li><li>Active Material Transfer Agreement indicates ongoing collaboration with major pharmaceutical firms.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Lexaria&#039;s DehydraTECH technology improves drug bio-absorption and delivery.</li><li>The GLP-1 market generated approximately $75 billion in revenue in 2025.</li><li>Lexaria holds 65 patents granted with more pending.</li><li>Five GLP-1 studies have been completed involving semaglutide and others.</li><li>The inaugural episode of the communication series is now available publicly.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider LEXX for potential upside as investor engagement improves visibility and credibility.</p>
  </section>
</section>


<article>
    <h2>Lexaria Bioscience (NASDAQ: LEXX) Launches Investor Video Series to Enhance Shareholder Engagement</h2>
    <p><strong>KELOWNA, BC / <a href='https://www.accessnewswire.com/'>ACCESS Newswire</a> / May 1, 2026 / </strong>Lexaria Bioscience Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/quote/LEXX">LEXX</a>), a pioneer in oral drug delivery technologies, has announced the debut of its ongoing investor communication initiative titled <em>Reformulated: Into the Mainstream</em>. This series aims to provide transparency and consistent interaction with shareholders and the general investment community.</p>

    <section>
        <h3>About the New Investor Video Series</h3>
        <p>The <em>Reformulated: Into the Mainstream</em> video series will include regular interviews and discussions led by Lexaria's management team. Designed to keep investors informed, the episodes will cover major updates about the company and provide insights into broader market trends, particularly within the GLP-1 and oral drug delivery sectors.</p>
    </section>

    <section>
        <h3>Inaugural Episode Highlights</h3>
        <p>The inaugural episode features a detailed conversation between Rich Christopher, CEO of Lexaria, and host Ana Berry. Key topics include:</p>
        <ul>
            <li>An overview of the DehydraTECH platform and its relevance to GLP-1 therapies, CBD, and antivirals.</li>
            <li>Insights into the GLP-1 market, which raked in approximately <strong>$75 billion</strong> globally in 2025.</li>
            <li>The conclusion of five human GLP-1 studies involving semaglutide, tirzepatide, and liraglutide.</li>
            <li>Lexaria's multifaceted commercial strategy, including ongoing outlicensing efforts under a Material Transfer Agreement with a global pharmaceutical firm.</li>
        </ul>
        <p>The first episode can be viewed here: <a rel="nofollow" href="https://pr.report/l7bp">https://www.youtube.com/watch?v=KG9dCWS6x6I</a>.</p>
    </section>

    <section>
        <h3>CEO's Commitment to Transparency</h3>
        <p>"Transparency and consistent communication are foundational to building long-term trust with shareholders," stated Rich Christopher. He emphasized that the video series is a reflection of Lexaria's determination to provide ongoing insights into their business strategies and the execution required to advance DehydraTECH toward lucrative commercial partnerships.</p>
        <p>Future episodes will delve into various aspects of Lexaria's clinical pipeline, intellectual property assets, and other important industry developments.</p>
    </section>

    <section>
        <h3>Company Overview: Lexaria Bioscience and DehydraTECH</h3>
        <p>DehydraTECH<sup>&#8482;</sup> is Lexaria’s patented technology designed to enhance drug absorption through oral delivery. This innovative platform has demonstrated the ability to:</p>
        <ul>
            <li>Increase bio-absorption.</li>
            <li>Minimize side effects.</li>
            <li>Improve the efficacy of various drugs across the blood-brain barrier.</li>
        </ul>
        <p>Lexaria boasts a substantial intellectual property portfolio, holding <strong>65 granted patents</strong> with more pending, and operates a licensed in-house research facility. For more information, visit <a rel="nofollow" href="https://pr.report/l7bq">www.lexariabioscience.com</a>.</p>
    </section>

    <section>
        <h3>Caution Regarding Forward-Looking Statements</h3>
        <p>This press release contains forward-looking statements as defined under applicable securities laws. Such statements involve risks and uncertainties, including but not limited to:</p>
        <ul>
            <li>Market conditions and regulatory approvals.</li>
            <li>Company's research and development capabilities.</li>
            <li>Possible adverse effects related to product testing.</li>
        </ul>
        <p>Any forward-looking statements should not be overly relied upon as actual results may differ from expectations. More details can be found in the company's filings with the US Securities and Exchange Commission.</p>
    </section>

    <section>
        <h3>Investor Contact Information</h3>
        <p>For inquiries, please contact:</p>
        <p>George Jurcic - Head of Investor Relations<br/>
        <a rel="nofollow" href="mailto:ir@lexariabioscience.com">ir@lexariabioscience.com</a><br/>
        Phone: 250-765-6424, ext. 202</p>
    </section>

    <footer>
        <p><strong>SOURCE:</strong> Lexaria Bioscience Corp.</p>
    </footer>
</article>

Lexaria Bioscience has launched an investor communication series focusing on its DehydraTECH platform and the lucrative GLP-1 market. The ongoing series aims to enhance transparency with shareholders and highlights the company's strategic advancements in oral drug delivery, suggesting a potential boost in investor confidence and stock performance.

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News